{"url_path":"/sec/spry/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1671858/0001193125-26-220671-index.html","accession_number":"0001193125-26-220671","cik":"0001671858","ticker":"SPRY","issuer_name":"ARS Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671858/0001193125-26-220671-index.html","primary_entity_key":"0001671858","primary_entity_name":"ARS Pharmaceuticals, Inc."},"word_count":90,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n\n  \n\nDescription\n\n10.1\n  \n[Executive Employment Agreement, dated May 12, 2026, between the Company and Donn Casale.](d10320dex101.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nARS PHARMACEUTICALS, INC.\n\nDate: May 13, 2026\n \n\n \nBy:\n \n\n/s/ Richard Lowenthal\n\n \n\n \n\n \nRichard Lowenthal, M.S., MSEL\n\n \n\n \n\n \nPresident and Chief Executive Officer"}